Q2 2014 13F Holders as of 6/30/2014
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
15.6M
-
Shares change
-
+317K
-
Total reported value, excl. options
-
$690M
-
Value change
-
+$13.8M
-
Put/Call ratio
-
0.7
-
Number of buys
-
42
-
Number of sells
-
-35
-
Price
-
$44.89
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2014
91 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2014.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.6M shares
of 96M outstanding shares and own 16.28% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (3.09M shares), Capital Research Global Investors (2.06M shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (1.79M shares), ADAGE CAPITAL PARTNERS GP LLC (1.76M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.25M shares), WELLINGTON MANAGEMENT CO LLP (625K shares), Visium Asset Management, LP (470K shares), Capital World Investors (362K shares), ALLIANCEBERNSTEIN L.P. (305K shares), and VANGUARD GROUP INC (273K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.